Malignant pheochromocytoma and paraganglioma: Future considerations for therapy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 2, 2013, Pages 153-160

  Buzzoni, R ^a   Pusceddu, S ^a   Damato, A ^a   Meroni, E ^a   Aktolun, C ^b   Milione, M ^a   Mazzaferro, V ^a   De Braud, F ^a   Spreafico, C ^a   Maccauro, M ^a   Zaffaroni, N ^a   Castellani, M R ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Molecular targeted therapy; Neuroendocrine tumors; Paraganglioma; Pheochromocytoma

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; AZD 8055; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SOMATOSTATIN DERIVATIVE; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER CELL; CARCINOGENESIS; CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CYTOREDUCTIVE SURGERY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; LONG TERM CARE; MOLECULARLY TARGETED THERAPY; PARAGANGLIOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; REVIEW; SCINTIGRAPHY; TUMOR VOLUME; UBIQUITINATION;

ADRENAL GLAND NEOPLASMS; DRUG THERAPY; FORECASTING; HUMANS; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; PARAGANGLIOMA;

EID: 84882311315     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Klein RD, Lloyd RV, Young WF: Hereditary paraganglioma-pheochromocitoma syndromes. In: Pagon RA, Dolan CR, Stephens K, editors. Gene reviews. Seatde, WA: University of Washington; 2009.
2. Chisolidou A, Kaltsas G, Ilias G, Grossman AB. The diagnosis and management of malignant pheochromocytoma and paraganglioma. Endocr Related Cancers 2007;14:569-85.
3. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Pheochromocytoma. Lancet 2005;366:665-75.
4. Eisenhofer G, Bimstein SR, Bronwers FM, Cheung NK, Dahia PL, De Krijer RR et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Related Cancers 2004;11:423-36.
5. Disick GI, Palese MA. Extra-adrenal pheochromocytoma: diagnosis and management. Curr Urol Rep 2007;8:83-8.
6. Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T et al. Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine and dacatbazine chemotherapy. J Clinic Endocrinal Metab 2009;94:2850-6.
7. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J et al. Succinate dehydrogenase B gene mutation predict serviva in patients with malignant pheochromocytomas or paragangliomas. J Clinic Endocrinol Metab 2007;92:3822-8.
8. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant pheochromocytomas. Cancer Res 2003;63:5615-21.
9. Rooijenes PP, de Krijer RR, Bonjer HJ, van der Ham F, Nigg AL, Bruining HA et al. The significance of angiogenesis in malignant pheochromocytomas. Endocr Pathol 2004;15:39-45.
10. Feng F, Zhu Y, Wang X, Wu Y, Zhou W, Jin X et al. Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol 2011;185:1583-90.
11. Domi R, Laho H. Management of pheochromocytoma: old ideas and new drugs. Niger J Clin Pract 2012;15:235-7.
12. Gedik GK, Hoefnagel CA, Bais E, Olmas RA. 1311-MibG therapy in metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008;35:725-33.
13. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A et al. Phase II study of Temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-6.
14. De WP, Oragano L, Rade F, Beaulieu A, Arnault V, Levillain P et al. Malignant pheochromocytoma: new malignancy criteria. Langenbecks Arch Surg 2012;397:239-46.
15. Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 2003;95:1196-204.
16. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1456-66.
17. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de PB, Chabre O et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005;23:8812-8.
18. Castellano M, Mori L, Giacche M, Agliozzo E, Tosini R, Panarotto A et al. Genetic mutation screening in an Italian color of nonsyndromic pheochromocytoma/paraganglioma patients. Ann N Y Acad Sci 2006;1073:156-65.
19. Korpershoek E, Van Nederveen FH, Dannenberg H, Petri BJ, Komminoth P, Perren A et al. Genetic analyses of apparently sporadic pheochromocytomas: the Rotterdam experience. Ann N Y Acad Sci 2006;1073:138-48.
20. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2ARET requie activation of the phosphatidylisitol 3-Kinase/AKT signaling pathway. J Biol Chem 2000;275:3568-76.
21. Brouwers FM, Elkaloun AG, Munson PJ, Eisenhofer G, Barb J, Linehan WM et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci 2006;1073:541-56.
22. Thouennon E, Elkahloun AG, Guillemot J, Gimenez-roqueplo AP, Bertherat J, Pierre A et al. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J Clin Endocrinol Metab 2007;92:4865-72.
23. Favier J, Igaz P, Burnichon N, Amar L, Libè R, Badoual C et al. Rationale for antioangiogenic therapy in pheochromocytoma and paraganglioma. Endoc Pathol 2012; 23:34-42.
24. Ohji H, Sasagawa I, Iciyanagi O, Suzuki Y, Nakada T. Tumour angiogenesis and Ki-67 expression in pheochromocytoma. BJU Int 2001;87:381-5.
25. Salmenkivi K, Heikkila P, Liu J, Haglund C, Arola J. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. Apmis 2003;111:458-64.
26. Aliabadi H, Vredenburg JJ, Everson RG, Desjardins A, Friedman HS, Mc Lendon RE et al. Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. J. Neurooncol 2010;98:427-30.
27. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004;3:1221-24.
28. Burnichon N, Lepontre-Lussey C, Laffaire J, Gadessaud N, Molinie V, Herningou A et al. A novel TMEM127 mutation in a patient with familiar bilateral pheochromocytoma. Eur J Endocrinol 2011;164:141-5.
29. Druce MR, Kaltas GA, Fraenkel M, Grass DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant pheochromocytoma: experience with the mTOR inhibitor Everolimus (RAD001). Horm Metab Res 2009;41:697-702.
30. Zitzmann K, Ruden J, Braud S, Goke B, Lichtl J, Spottl G et al. Compensatory activation of AKT in response to mTOR and Raf inhibitors - a rationale for dual targeted therapy approaches in neuroendocrine tumor disease cancer. Lett 2010;295:100-9.
31. Martiniova L, Lai EW, Elkahloun AG, Abu-Asab M, Wickremasinghe A, Solis DC et al. Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. Clin Exp Metastasis 2009;26:239-50.
32. Nölting S, Grossman AB. Signaling pathways in pheochromocytomas and paragangliomas: prospect for future therapies. Endocr Pathol 2012;23:21-33.
33. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M et al. Rationale and evidence for Sunitinib in the treatment of malignant paraganglioma/ pheochromocytoma. J Clin Endocrinol Metab 2009;94:5-9.
34. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA et al. Use of the tyrosine kinase inhibitor Sunitinib in a patient with von Hippel-Lndau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 2009;94:386-91.
35. Santarpia L, Hambra MA, Jimenez C. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies. Horm Metab Res 2009;41:680-6.
36. Hahn NM, Reckova M, Cheng L, Baldridge LA, Cumming OW, Sweeney CJ. Patient with malignant paraganglioma responding to the multikinase inhibitor Sunitinib malate. J Clin Oncol 2009;27:460-3.
37. Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS et al. Sunitinib, a novel therapy for anthracycline -and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol 2009;39:327-31.
38. Former C, Minnemann T, Kalmbach S, Weber MM. Overexpression of the insulin-like growth factor I receptor in human pheochromocytoma. J Mol Endocrinol 2006;36:279-87.
39. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007;12:853-9.
40. Welsh S, Williams R, Kirkpatrick I, Paine-murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, as inhibitor of hypoxia-inducible factor-lalpha. Mol Cancer Ther 2004;3:233-44.
41. Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giachè V, Mannelli M. Update and new prospective on diagnosis, prognosis and therapy of malignant pheochromocytoma/paraganglioma. J Oncol 2012;2012:872713.
42. Zukanskaite R, Hjorthgan K, Poulsen PL, Baerentzen S, Laderkarl M. Malignant pheochromocytoma and paraganglioma: three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs. Acta Oncologica 2011;50:1255-9.
43. Tai'eb D, Timmers HJ, Hindiè E, Guillet BA, Neumann HP, Walz MK et al. EANM guidelines for radionuclide imaging of pheochromocytoma and paraganglioma. Eur J. Nucl Med Mol Imaging 2012 [In press].